Head and Neck Cancer Clinical Trials

**Correlative**

- **UCI 14-25** Plasma Exosome Concentration in Cancer Patients Undergoing Treatment (Nelson)

- **UCI 16-01** (PAINT Cancer)-Pathway Analyses for Individualized Network Therapeutics for Cancer (Nelson)

**Neo-Adjuvant - Squamous Cell Carcinoma**

- **UCI 16-72** Randomized Double-Blind Phase 3 Study of Avelumab in Combination with Standard of Care Chemoradiotherapy (Cisplatin Plus Definitive Radiation Therapy) Versus Standard of Care Chemoradiotherapy in the Front-Line Treatment of Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Ejadi)

**Neo-Adjuvant - Nasopharyngeal**

- **NRG-HN001** Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA) (Ejadi)

For more details contact 1-877-UC-STUDY OR ucstudy@uci.edu

**Opening soon**
Head and Neck Cancer Clinical Trials

** HEAD & NECK CANCER **

Metastatic

UCI 16-50 Phase 1b/2, Open-Label, Multicenter Study Assessing the Safety, Tolerability, Pharmacokinetics & Preliminary Anti-tumor Activity of MEDI4736 in Combination With AZD9150 or AZD5069 in Pts With Advanced Solid Malignancies & Subsequently Comparing AZD9150 & AZD5069 Both as Monotherapy & in Combination With MEDI4736 as Second Line Treatment in Pts With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (Nelson)

UCI 16-96 A Phase I Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors (Ou)

ECOG EAY131 Molecular Analysis for Therapy Choice (MATCH) (Larynx, Lip, Oral Cavity & Pharynx) (Bota)

SWOG S1609 DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (Bota)

UCI 18-14 A Phase I, Open-Label, Multicenter Dose Escalation Study of RMC-4630 Monotherapy in Adult Patients with Relapsed/Refractory Solid Tumors (Ou)

UCI 18-19 An Open-Label, Phase Ib Multicenter Study of IBI308 in Subjects with Advanced/Metastatic Solid Malignancies (Zhu)

UCI 18-21 ** A Phase I/II Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors with RET Activation (LIBRETTO-001) (Ou)

** Opening soon **